On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm

SUMMARY There has been a recent emphasis on the identification of biomarkers and other biologic measures that may be potentially used as surrogate endpoints in clinical trials. We focus on the setting of data from a single clinical trial. In this article, we consider a framework in which the surrogate must occur before the true endpoint. This suggests viewing the surrogate and true endpoints as semicompeting risks data; this approach is new to the literature on surrogate endpoints and leads to an asymmetrical treatment of the surrogate and true endpoints. However, such a data structure also conceptually complicates many of the previously considered measures of surrogacy in the literature. We propose novel estimation and inferential procedures for the relative effect and adjusted association quantities proposed by Buyse and Molenberghs (1998, Biometrics 54, 1014-1029). The proposed methodology is illustrated with application to simulated data, as well as to data from a leukemia study.

[1]  Thomas A. Louis,et al.  Nonparametric analysis of an accelerated failure time model , 1981 .

[2]  Janice Gabrilove,et al.  Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia , 1991 .

[3]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[4]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[5]  Rodolphe Thiébaut,et al.  Counterfactual Links to the Proportion of Treatment Effect Explained by a Surrogate Marker , 2005, Biometrics.

[6]  Wei-Yann Tsai,et al.  Testing the assumption of independence of truncation time and failure time , 1990 .

[7]  D. Oakes,et al.  Semiparametric inference in a model for association in bivanate survival data , 1986 .

[8]  R. Day,et al.  Adaptation of bivariate frailty models for prediction, with application to biological markers as prognostic indicators , 1997 .

[9]  Debashis Ghosh,et al.  Semiparametric inferences for association with semi‐competing risks data , 2006, Statistics in medicine.

[10]  D. Cox.  Regression Models and Life-Tables , 1972 .

[11]  D. Harrington,et al.  Counting Processes and Survival Analysis , 1991 .

[12]  G. Molenberghs,et al.  Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.

[13]  Geert Molenberghs,et al.  Statistical challenges in the evaluation of surrogate endpoints in randomized trials. , 2002, Controlled clinical trials.

[14]  James M. Robins,et al.  An analytic method for randomized trials with informative censoring: Part II , 1995, Lifetime data analysis.

[15]  Nancy Reid,et al.  On “A conversation with Sir David Cox” , 1994, Issue 5.2, Spring 2023.

[16]  D. Rubin,et al.  Principal Stratification in Causal Inference , 2002, Biometrics.

[17]  Jeremy M G Taylor,et al.  A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker , 2002, Biometrics.

[18]  Weijing Wang,et al.  Estimating the association parameter for copula models under dependent censoring , 2003 .

[19]  D. Oakes.  A Model for Association in Bivariate Survival Data , 1982 .

[20]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[21]  G. Molenberghs,et al.  Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .

[22]  V De Gruttola,et al.  Estimating the proportion of treatment effect explained by a surrogate marker. , 1997, Statistics in medicine.

[23]  C. Begg,et al.  On the Use of Surrogate Endpoints in Randomized Trials (with Discussion) , 2000 .

[24]  R J Carroll,et al.  On meta-analytic assessment of surrogate outcomes. , 2000, Biostatistics.

[25]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .

[26]  James M. Robins,et al.  Comparing two failure time distributions in the presence of dependent censoring , 1996 .

[27]  Z. Ying,et al.  A simple resampling method by perturbing the minimand , 2001 .

[28]  Jason P. Fine,et al.  On semi-competing risks data , 2001 .

[29]  Martin T. Wells,et al.  Model Selection and Semiparametric Inference for Bivariate Failure-Time Data , 2000 .

[30]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[31]  R. Nelsen.  An Introduction to Copulas , 1998 .

[32]  D. Oakes,et al.  Bivariate survival models induced by frailties , 1989 .

[33]  Z. Ying,et al.  Rank-based inference for the accelerated failure time model , 2003 .

[34]  Geert Molenberghs,et al.  Evaluation of Surrogate Endpoints , 2006, Handbook of Statistical Methods for Randomized Controlled Trials.

[35]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[36]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[37]  Zhiliang Ying,et al.  A Large Sample Study of Rank Estimation for Censored Regression Data , 1993 .

[38]  Vance W Berger,et al.  Does the Prentice criterion validate surrogate endpoints? , 2004, Statistics in medicine.

[39]  D. Clayton.  A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence , 1978 .

[40]  Limin Peng,et al.  Rank Estimation of Accelerated Lifetime Models With Dependent Censoring , 2006 .

[41]  M J Daniels,et al.  Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.

[42]  Debashis Ghosh,et al.  Semiparametric Inference for Surrogate Endpoints with Bivariate Censored Data , 2008, Biometrics.

[43]  Z. Ying,et al.  A resampling method based on pivotal estimating functions , 1994 .

[44]  C. Begg,et al.  On the use of surrogate end points in randomized trials , 2000 .

[45]  Donald B. Rubin,et al.  Estimation of Causal Effects via Principal Stratification When Some Outcomes are Truncated by “Death” , 2003 .

[46]  Daniel J Sargent,et al.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.